FindTrial
Sign In

A placebo-controlled trial of nimodipine with cyclophosphamide/cisplatin for the treatment of advanced ovarian cancer

A placebo-controlled trial of nimodipine with cyclophosphamide/cisplatin for the treatment of advanced ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN66284161
Enrollment
Unknown
Registered
2001-07-01
Start date
1989-01-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer Cancer Ovarian cancer

Interventions

1. Arm A: Placebo tablet 2. Arm B: Nimopidine tablet

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of invasive epithelial ovarian cancer 2. International Federation of Gynaecology and Obstetrics (FIGO) stages Tc - Tv 3. 18-70 years old 4. Performance Status less than or equal to 2 5. White Blood Cells at least 4 x 10^9/l 6. Platelets at least 120 x 10^9/l 7. Creatinine or Ethylene Diamine Tetraacetic Acid (EDTA) clearance greater than or equal to 60 ml/min 8. Normal Bilirubin 9. Serum glutamic-oxaloacetic transaminase (SGOT)/Serum glutamic pyruvic transaminase (SGPT) less than or equal to twice normal limit 10. No previous chemotherapy or radiotherapy

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026